View my full bio
See more of my posts
Tweet this article
Comment on articleUnder the terms of the agreement, GeneMachines will sell its OmniGrid and OmniGrid Accent microarrays with a label license for research use that allows end-users to practice the methods of printing microarrays.
"We are excited to have worldwide licensing rights to this enabling technology which has become invaluable to genomics research," said Scott Hunicke-Smith, President and CEO of GeneMachines. "We expect that access to this proprietary technology will bring even greater value to our successful microarraying program."
blog comments powered by Disqus
